Pfizer, still chasing Dupixent, releases fifth round of data for eczema JAK inhibitor abrocitinib
Over the last several months, Pfizer has been putting together a profile of several Phase III trials for its experimental JAK1 inhibitor abrocitinib to take to regulators, in the hopes of taking down Dupixent. And on Wednesday, the big pharma released another set of positive topline data.
In what’s now the fifth Phase III to report abrocitinib data, Pfizer said fewer patients with atopic dermatitis experienced a flare up after 52 weeks at multiple dosage levels over placebo. The study, which enrolled 1,233 patients 12 and older, involved a 12-week induction followed by a 40-week blinded maintenance period.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.